Evidence map›Paper›PMID 32586763›Full record

ArticleVaccine2020

Vaccine implementation factors affecting maternal tetanus immunization in low- and middle-income countries: Results of the Maternal Immunization and Antenatal Care Situational Analysis (MIACSA) project.

M L Giles, C Mantel, F M Muñoz, A Moran, N Roos, N Yusuf, T Diaz, M Ahun, L M Nic Lochlainn, E Wootton and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Stakeholder Perceptions About Group B Streptococcus Disease and Potential for Maternal Vaccination in Low- and Middle-Income Countries.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  15. Vaccination in pregnancy: The role of the midwife.Frontiers in global women's health · 2022
    Article
  16. Maternal RSV vaccine development. Where to from here?Human vaccines & immunotherapeutics · 2021
    Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 4 countries.

M L GilesDepartment of Obstetrics and Gynaecology, Monash University, Melbourne, Australia. Electronic address: michelle.giles@monash.edu.
C MantelMMGH Consulting, Zurich, Switzerland.
F M MuñozDepartments of Pediatrics, Section of Infectious Diseases, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston TX, USA.
A MoranDepartment of Maternal, Newborn, Child, Adolescent Health and Ageing, Geneva, Switzerland.
N RoosDepartment of Maternal, Newborn, Child, Adolescent Health and Ageing, Geneva, Switzerland.
N YusufDepartment of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.
T DiazDepartment of Maternal, Newborn, Child, Adolescent Health and Ageing, Geneva, Switzerland.
M AhunIndependent Consultant, McKing Consulting, Geneva, Switzerland.
L M Nic LochlainnDepartment of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.
E WoottonDepartment of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.
J PathiranaMedical Research Council: Respiratory and Meningeal Pathogens Research Unit and Department of Science and Technology/ National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
S RendellDepartment of Anthropology University of Pennsylvania, Philadelphia, USA.
O TuncalpDepartment of Sexual and Reproductive Health and Research including UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, WHO, Geneva, Switzerland.
M PerutDepartment of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.
J HombachDepartment of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.
S MertenSwiss Tropical and Public Health Institute and University of Basel, Basel, Switzerland.
P LambachDepartment of Immunization, Vaccines and Biologicals (IVB), World Health Organization, Geneva, Switzerland.
World Health Organization · CHBaylor College of Medicine · USMonash Health · AUSwiss Tropical and Public Health Institute · CHUniversity of Pennsylvania · USUniversity of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo examine the characteristics of existing maternal tetanus immunization programmes for pregnant women in low- and middle-income countries (LMICs) and to identify and understand the challenges, barriers and facilitators associated with maternal vaccine service delivery that may impact the introduction and implementation of new maternal vaccines in the future.

designA mixed methods, cross sectional study with four data collection phases including a desk review, online survey, telephone and face-to-face interviews and in country visits.

settingLMICs.

resultsThe majority of countries (84/95; 88%) had a maternal tetanus immunization policy. Countries with high protection at birth (PAB) were more likely to report tetanus toxoid-containing vaccine (TTCV) coverage targets > 90%. Less than half the countries included in this study had a TTCV coverage target of > 90%. Procurement and distribution of TTCV was nearly always the responsibility of the Expanded Programme on Immunization (EPI), however planning and management of maternal immunization was often shared between EPI and Maternal, Newborn and Child Health (MNCH) programmes. Receipt of TTCV at the same time as the antenatal care visit correlated with high PAB. Most countries (81/95; 85%) had an immunization safety surveillance system in place although only 11% could differentiate an adverse event following immunization (AEFI) in pregnant and non-pregnant women.

conclusionsRecommendations arising from the MIACSA project to strengthen existing services currently delivering maternal tetanus immunization in LMICs include establishing and maintaining vaccination targets, clearly defining responsibilities and fostering collaborations between EPI and MNCH, investing in strengthening the health workforce, improving the design and use of existing record keeping for immunization, adjusting current AEFI reporting to differentiate pregnant women and endeavoring to integrate the provision of TTCV within ANC services where appropriate.

Indexed as

Developing CountriesTetanusChildCross-Sectional StudiesFemaleHumansImmunizationInfant, NewbornPregnancyPrenatal CareVaccinationLMICs, MIACSAMaternal ImmunizationPregnancyService DeliveryTetanusVaccination

Identifiers

PMID32586763
PMCPMC7342017
OpenAlexW3035778484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.